Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in Recurrent or Unresectable Giant Cell Tumor of Bone
NCT00396279Phase 2Completed
- Sponsor
- Amgen
- Start
- Jul 2006
- Primary completion
- Apr 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of denosumab in Giant Cell Tumor of Bone (GCTB), sponsored by Amgen. Started Jul 2006; status: completed.
02
Drugs
denosumab
03
Conditions
Giant Cell Tumor of Bone (GCTB)
Beyond the preview
Go deeper on NCT00396279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00396279.